Therapeutic lymphangiogenesis using stem cell and VEGF-C hydrogel

Area of Science:

• Regenerative Medicine
• Vascular Biology
• Biomaterials Science

Background:

• Lymphedema results from lymphatic system insufficiency, often requiring lifelong management.
• Current treatments offer symptomatic relief but do not address the underlying lymphatic dysfunction.
• Vascular Endothelial Growth Factor C (VEGF-C) shows promise for molecular-based lymphedema therapies.

Purpose of the Study:

• To evaluate the therapeutic potential of human adipose-derived stem cells (hADSCs) combined with VEGF-C hydrogel in a lymphedema mouse model.
• To determine if VEGF-C hydrogel enhances the efficacy of hADSC implantation for lymphedema treatment.
• To assess the impact on edema reduction and lymphatic vessel regeneration.

Main Methods:

• A lymphedema mouse model was established.
• Mice were treated with hADSCs, VEGF-C hydrogel, or a combination of both.
• Edema depth was measured, and lymphatic vessel density was assessed via immunohistochemistry.
• PKH-labeled hADSCs were tracked, and their differentiation was confirmed using LYVE-1 co-staining.

Main Results:

• The combination of hADSCs and VEGF-C hydrogel significantly reduced dermal edema compared to monotherapies.
• Lymphatic vessel regeneration was markedly enhanced in the hADSC/VEGF-C hydrogel group.
• Implanted hADSCs survived, integrated, and differentiated into lymphatic endothelial cells.

Conclusions:

• Co-administration of hADSCs and VEGF-C hydrogel demonstrates a substantial positive effect on lymphangiogenesis.
• This combination therapy offers a promising strategy for treating lymphedema by promoting lymphatic repair.
• The findings support the use of biomaterial-enhanced stem cell therapy for lymphatic regeneration.